8.65
+0.34(+4.09%)
Currency In USD
| Previous Close | 8.31 |
| Open | 8.37 |
| Day High | 8.76 |
| Day Low | 8.37 |
| 52-Week High | 9.04 |
| 52-Week Low | 1.78 |
| Volume | 863,608 |
| Average Volume | 2.19M |
| Market Cap | 1.5B |
| PE | -5.03 |
| EPS | -1.72 |
| Moving Average 50 Days | 7.22 |
| Moving Average 200 Days | 4.45 |
| Change | 0.34 |
If you invested $1000 in Relay Therapeutics, Inc. (RLAY) since IPO date, it would be worth $246.79 as of December 25, 2025 at a share price of $8.65. Whereas If you bought $1000 worth of Relay Therapeutics, Inc. (RLAY) shares 3 years ago, it would be worth $600.28 as of December 25, 2025 at a share price of $8.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
GlobeNewswire Inc.
Dec 12, 2025 12:00 PM GMT
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer,
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November
GlobeNewswire Inc.
Nov 03, 2025 9:05 PM GMT
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic dise
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 8:05 PM GMT
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies,